Results 121 to 130 of about 13,497 (214)

Association of GLP‐1 Receptor Agonist Prescriptions and Alcohol Consumption in the National Institutes of Health's All of Us Cohort

Alcohol, Clinical and Experimental Research, Volume 50, Issue 7, July 2026.
This cohort study examined whether GLP‐1 receptor agonist prescriptions are associated with alcohol use among NIH All of Us participants. Those with current GLP‐1RA prescriptions showed modestly lower AUDIT‐C scores compared to those with future prescriptions. GLP‐1RAs may reduce alcohol consumption by reducing drinking frequency.
Benjamin Tyndall, Angela Gasdaska, M. Daniel Brannock, Ed Preble, Melissa McPheeters, Laura Marcial, Ariba Huda, Josephine Egan, Tamara R. Litwin, Jennifer Adjemian, Chandan Sastry, Mehdi Farokhnia, Lorenzo Leggio   +12 more
wiley   +1 more source

A systematic review and meta‐analysis of the relative benefit of dual versus single oral hypoglycaemic therapy following diagnosis with type 2 diabetes (T2D)

Diabetic Medicine, Volume 43, Issue 7, July 2026.
Abstract Introduction Achieving and sustaining target glycated haemoglobin (HbA1c) levels is fundamental in the management of type 2 diabetes (T2D). We here aimed to assess whether initial dual oral therapy outperforms monotherapy in reaching glycaemic targets in patients with treatment‐naive or early‐stage T2D.
Mairead Kelly, Sushant Saluja, Hugh Logan Ellis, Sarah Jamil, Martin B. Whyte, Adrian Heald   +5 more
wiley   +1 more source

Genetic variants of glucose-dependent insulinotropic polypeptide (GIP) signalling as proxy for body weight reduction and cardiovascular risk. [PDF]

Eur Heart J
Emanuelsson F, Nordestgaard BG, Benn M.
europepmc   +1 more source

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5915-5925, July 2026.
ABSTRACT Aims Petrelintide is a long‐acting amylin analogue in development for weight management. The safety, tolerability, pharmacokinetics, and pharmacodynamics of petrelintide were evaluated in single ascending dose (SAD) and multiple ascending dose (MAD) trials. Materials and Methods Both trials were randomized, placebo‐controlled, and double‐blind.
Minna Brændholt Olsen, Jon Griffin, Ulrike Hövelmann, Stanislava Macura, Berith Fredsted Hagen, Dan Hesse, Tim Heise   +6 more
wiley   +1 more source

Impact of Simulated Risk Factor Management on Cardiovascular Disease and Costs in Type 2 Diabetes Using the ABC Model

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5670-5683, July 2026.
ABSTRACT Aims We evaluated the impact of scenario‐based multifactorial control on the 3‐year incidence of fatal/non‐fatal cardiovascular disease (CVD) and associated healthcare costs in Asian patients with type 2 diabetes (T2D). Materials and Methods We applied the validated ‘ABC’ model to simulate the 3‐year impact of attaining multiple treatment ...
Lee‐Ling Lim, Eric S. H. Lau, Juliana N. M. Lui, Linong Ji, A. G. Unnikrishnan, Sirinart Sirinvaravong, Siew‐Pheng Chan, Soo Lim, Andrea O. Y. Luk, Juliana C. N. Chan   +9 more
wiley   +1 more source

Tirzepatide and Weight Management

JK Science
Tirzepatide is a once-weekly dual agonist, that acts on glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.
Vishal R. Tandon, Annil Mahajan
doaj  

Semaglutide Treatment in Young Adults Living With Type 2 Diabetes: A Post Hoc Analysis From the SUSTAIN and PIONEER Clinical Trials

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5787-5802, July 2026.
ABSTRACT Aims Young adults (aged ≤ 40 years) are underrepresented in clinical trials that investigate interventions for those living with Type 2 diabetes (T2D). This study evaluated the efficacy of semaglutide treatment in young adults with T2D by examining the effects on HbA1c and body weight (BW) during the SUSTAIN and PIONEER programmes compared to ...
Francesco Zaccardi, Vanita R. Aroda, Ecenur Guder Arslan, Lars Bardtrum, Jonathan Goldney, Erik Ising, Prachi Priyadarshini, Tommy Slater, Melanie J. Davies   +8 more
wiley   +1 more source

Interaction between fatty pancreas disease and genetically predicted glucose-dependent insulinotropic polypeptide on incident type 2 diabetes: evidence from the UK Biobank. [PDF]

Front Endocrinol (Lausanne)
Wang X, Yang Y, Han S, Liu Z, Ping F, Li W, Xu L, Zhang H, Li Y.   +8 more
europepmc   +1 more source

Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 6162-6171, July 2026.
ABSTRACT Aims Tirzepatide, an injectable glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) receptor agonist (RA), is approved for weight management in several regions. Oral GLP‐1 RAs, such as semaglutide, are under investigation to improve convenience, acceptance and adherence versus injectable formulations ...
Andreea Ciudin, Erin Johansson, Sarah Zimner‐Rapuch, Georgios K. Dimitriadis, Mathias Hempfling, Laura J. Clark, Ludi Fan, Helene Sapin   +7 more
wiley   +1 more source

Association of Glucose‐Dependent Insulinotropic Polypeptide Levels With Cardiovascular Mortality in Patients With Acute Myocardial Infarction

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Florian Kahles, Marcia V. Rückbeil, Maria C. Arrivas, Robert W. Mertens, Julia Moellmann, Moritz Biener, Evangelos Giannitsis, Hugo A. Katus, Nikolaus Marx, Michael Lehrke   +9 more
doaj   +1 more source